Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/INTELLIA-THERAPEUTICS-INC-27506682/news/Intellia-Therapeutics-Doses-First-Patient-in-Landmark-CRISPR-Cas9-Clinical-Trial-of-NTLA-2001-for-31725739/?utm_source=whatsapp&utm_medium=social&utm_campaign=share